A Quick Take: Celsion’s ThermoDox Phase III Failure Deals Blow To China’s Hisun
This article was originally published in PharmAsia News
Executive Summary
With the ink barely dry in a deal between U.S. biotech Celsion and Chinese active ingredient manufacturer Hisun for Celsion’s leading oncology candidate ThermoDox, a Phase III study has thrown both into turmoil.